Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.

MLA

Shimose, Shigeo, et al. “Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.” Cancers, vol. 13, no. 1, Jan. 2021. EBSCOhost, https://doi.org/10.3390/cancers13010160.

APA

Shimose, S., Iwamoto, H., Tanaka, M., Niizeki, T., Shirono, T., Noda, Y., Kamachi, N., Okamura, S., Nakano, M., Suga, H., Yamaguchi, T., Kawaguchi, T., Kuromatsu, R., Noguchi, K., Koga, H., & Torimura, T. (2021). Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers, 13(1). https://doi.org/10.3390/cancers13010160

Chicago

Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, et al. 2021. “Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.” Cancers 13 (1). doi:10.3390/cancers13010160.